95 related articles for article (PubMed ID: 29374714)
1. Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.
Valan CD; Slagsvold JE; Halvorsen TO; Herje M; Bremnes RM; Brunsvig PF; Brustugun OT; Fløtten Ø; Levin N; Sundstrøm SH; Grønberg BH
Anticancer Res; 2018 Feb; 38(2):871-876. PubMed ID: 29374714
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM
Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924
[TBL] [Abstract][Full Text] [Related]
3. Duration of Twice-Daily Thoracic Radiotherapy and Time From the Start of Any Treatment to the End of Chest Irradiation as Significant Predictors of Outcomes in Limited-Disease Small-Cell Lung Cancer.
Morimoto M; Okishio K; Akira M; Omachi N; Tamiya A; Asami K; Kawaguchi T; Atagi S
Clin Lung Cancer; 2017 Mar; 18(2):e117-e127. PubMed ID: 28340925
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Grønberg BH; Halvorsen TO; Fløtten Ø; Brustugun OT; Brunsvig PF; Aasebø U; Bremnes RM; Tollåli T; Hornslien K; Aksnessæther BY; Liaaen ED; Sundstrøm S;
Acta Oncol; 2016 May; 55(5):591-7. PubMed ID: 26494411
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.
Halvorsen TO; Sundstrøm S; Fløtten Ø; Brustugun OT; Brunsvig P; Aasebø U; Bremnes RM; Kaasa S; Grønberg BH
Acta Oncol; 2016 Nov; 55(11):1349-1354. PubMed ID: 27549509
[TBL] [Abstract][Full Text] [Related]
6. Sequential Versus Concurrent Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for N3 Limited-Stage Small-Cell Lung Cancer.
Wang Z; Wan J; Liu C; Li L; Dong X; Geng H
Cancer Control; 2020; 27(1):1073274820956619. PubMed ID: 32951452
[TBL] [Abstract][Full Text] [Related]
7. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C
JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977
[TBL] [Abstract][Full Text] [Related]
8. Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.
Halvorsen TO; Herje M; Levin N; Bremnes RM; Brustugun OT; Fløtten Ø; Kaasa S; Sundstrøm S; Grønberg BH
Lung Cancer; 2016 Dec; 102():9-14. PubMed ID: 27987595
[TBL] [Abstract][Full Text] [Related]
9. Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey.
Bayman E; Etiz D; Akcay M; Ak G
Asian Pac J Cancer Prev; 2014; 15(15):6263-7. PubMed ID: 25124609
[TBL] [Abstract][Full Text] [Related]
10. Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer.
Han TJ; Kim HJ; Wu HG; Heo DS; Kim YW; Lee SH
Jpn J Clin Oncol; 2012 Oct; 42(10):948-54. PubMed ID: 22811409
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
Okamoto K; Okamoto I; Takezawa K; Tachibana I; Fukuoka M; Nishimura Y; Nakagawa K
Jpn J Clin Oncol; 2010 Jan; 40(1):54-9. PubMed ID: 19837690
[TBL] [Abstract][Full Text] [Related]
12. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses.
Hu X; Bao Y; Xu YJ; Zhu HN; Liu JS; Zhang L; Guo Y; Jin Y; Wang J; Ma HL; Xu XL; Song ZB; Tang HR; Peng F; Fang M; Kong Y; Chen MY; Dong BQ; Zhu L; Yu C; Yu XM; Hong W; Fan Y; Zhang YP; Chen PC; Zhao Q; Jiang YH; Zhou XM; Chen QX; Sun WY; Mao WM; Chen M
Cancer; 2020 Feb; 126(4):840-849. PubMed ID: 31714592
[TBL] [Abstract][Full Text] [Related]
13. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
Colaco R; Sheikh H; Lorigan P; Blackhall F; Hulse P; Califano R; Ashcroft L; Taylor P; Thatcher N; Faivre-Finn C
Lung Cancer; 2012 Apr; 76(1):72-7. PubMed ID: 22014897
[TBL] [Abstract][Full Text] [Related]
14. Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.
Lee J; Kim JO; Jung CK; Kim YS; Yoo IeR; Choi WH; Jeon EK; Hong SH; Chun SH; Kim SJ; Kim YK; Kang JH
Clin Lung Cancer; 2014 Mar; 15(2):e13-21. PubMed ID: 24368212
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
17. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer.
Killingberg KT; Halvorsen TO; Fløtten Ø; Brustugun OT; Langer SW; Nyman J; Hornslien K; Madebo T; Schytte T; Risum S; Tsakonas G; Engleson J; Grønberg BH
Lung Cancer; 2022 Apr; 166():49-57. PubMed ID: 35183991
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
Saito H; Takada Y; Ichinose Y; Eguchi K; Kudoh S; Matsui K; Nakagawa K; Takada M; Negoro S; Tamura K; Ando M; Tada T; Fukuoka M;
J Clin Oncol; 2006 Nov; 24(33):5247-52. PubMed ID: 17114657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
